AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16470086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15009817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose clonidine (25 micro g)
Number of subjects: 15
Study 15009817 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose clonidine (150 micro g)
Number of subjects: 15
Study 10968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microg x puff(‐1)) via metered-dose inhaler (MDI) under pressure control (decelerating flow pattern)
Number of subjects: 18
Study 10968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg) via MDI under volume control (square wave flow pattern)
Number of subjects: 18
Study 10968501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (600 microg) via MDI under volume control (square wave flow pattern)
Number of subjects: 18
Study 9247980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 gas mixture
Number of subjects: 68
Study 9247980 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of compressed air (control)
Number of subjects: 68
Study 7878168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg/kg body weight i.v.)
Number of subjects: 8
Study 7878168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7878168 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobic stimulation
Number of subjects: 8
Study 7878168 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral stimulation
Number of subjects: 8
Study 2094946 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release salbutamol (Group B)
Number of subjects: 20
Study 2094946 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (Group A)
Number of subjects: 20
Study 367406 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin treatment (aimed at maintaining plasma phenytoin levels between 40 and 80 mumol/litre)
Number of subjects: 150
Study 367406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenytoin treatment)
Number of subjects: 150
Study 367406 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin treatment
Number of subjects: 150
Study 31995556 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TAF
Number of subjects: 150
Study 31995556 — intervention group
Group type: COMPARATOR
Intervention: R/F/TAF
Number of subjects: 150
Study 31995556 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Number of subjects: 150
Study 30855502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated pedicle screws
Number of subjects: 28
Study 30855502 — intervention group
Group type: COMPARATOR
Intervention: Conventional pedicle screws
Number of subjects: 28
Study 27870553 — intervention group
Group type: EXPERIMENTAL
Intervention: NIO® (New Intraosseous Persys Medical)
Number of subjects: 50
Study 27870553 — intervention group
Group type: COMPARATOR
Intervention: EZ‐IO® (Teleflex Medical)
Number of subjects: 50
Study 27870553 — intervention group
Group type: EXPERIMENTAL
Intervention: NIO® and EZ‐IO®
Number of subjects: 50
Study 27870553 — intervention group
Group type: COMPARATOR
Intervention: EZ‐IO®
Number of subjects: 50
Study 26185394 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 87
Study 26185394 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 87
Study 24240641 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tape
Number of subjects: 24
Study 24240641 — intervention group
Group type: COMPARATOR
Intervention: Paper tape
Number of subjects: 24
Study 22564709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (20 µg once daily)
Number of subjects: 311
Study 22564709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 19897413 — intervention group
Group type: EXPERIMENTAL
Intervention: 9g Sodium Oxybate (SXB)
Number of subjects: 60
Study 19897413 — intervention group
Group type: EXPERIMENTAL
Intervention: 9g Sodium Oxybate (SXB) + 200mg Modafinil
Number of subjects: 60
Study 19897413 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg Zolpidem
Number of subjects: 60
Study 19897413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 60
Study 17673575 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15588905 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal iontophoretic delivery of R‐apomorphine with surfactant formulation pretreatment
Number of subjects: 16
Study 15588905 — intervention group
Group type: COMPARATOR
Intervention: Transdermal iontophoretic delivery of R‐apomorphine without surfactant formulation (control)
Number of subjects: 16
Study 12122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericin B + oral itraconazole
Number of subjects: 129
Study 12122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole + oral itraconazole
Number of subjects: 129
Study 12122510 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and oral placebo
Number of subjects: 129
Study 10619648 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 ERPs (go and no-go)
Number of subjects: 0
Study 10619648 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 ERPs
Number of subjects: 0
Study 10619648 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 ERPs
Number of subjects: 0
Study 8537671 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐valent pneumococcal conjugate vaccine (7‐OMPC) followed by one dose of 23‐valent polysaccharide pneumococcal vaccine (23‐PS)
Number of subjects: 39
Study 8537671 — intervention group
Group type: COMPARATOR
Intervention: 23‐valent polysaccharide pneumococcal vaccine (23‐PS) only
Number of subjects: 39
Study 1864539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eudragit S coated 5 amino salicylic acid (n = 12)
Number of subjects: 33
Study 1864539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal prednisolone enemas (n = 15)
Number of subjects: 33
Study 1864539 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 33
Study 6357175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole injection and placebo suppository
Number of subjects: 283
Study 6357175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole suppository and cotrimoxazole injection
Number of subjects: 283
Study 6357175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole suppository and placebo injection
Number of subjects: 283
Study 6357175 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository and placebo injection
Number of subjects: 283
Study 31575699 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab prophylaxis
Number of subjects: 397
Study 31575699 — intervention group
Group type: COMPARATOR
Intervention: No eculizumab prophylaxis
Number of subjects: 397
Study 31575699 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab use
Number of subjects: 397
Study 28028076 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate
Number of subjects: 0
Study 28028076 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 25937539 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 80
Study 25937539 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80
Study 23222095 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine taper (7 vs 28 days)
Number of subjects: 516
Study 21272849 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter left in place for a maximum of 24 hours
Number of subjects: 397
Study 21272849 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter left in place for a maximum of 12 hours
Number of subjects: 397
Study 21272849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) controlled-release vaginal insert
Number of subjects: 397
Study 19304880 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron transdermal patch (52 cm²)
Number of subjects: 793
Study 19304880 — intervention group
Group type: COMPARATOR
Intervention: Oral granisetron (2 mg)
Number of subjects: 793
Study 16730534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid treatment (0.5 mL of methylprednisolone acetate, 80 mg/2 mL, administered 4 times over 15 days)
Number of subjects: 37
Study 16730534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intratympanic treatment)
Number of subjects: 37
Study 15583586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin
Number of subjects: 0
Study 15583586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12577354 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuhuang Granule No. 2 (ZHG2)
Number of subjects: 67
Study 12577354 — intervention group
Group type: COMPARATOR
Intervention: Composite indigo capsule (control)
Number of subjects: 67
Study 1426320 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a initiation on cycle day 21 before COH (group I)
Number of subjects: 55
Study 1426320 — intervention group
Group type: COMPARATOR
Intervention: GnRH-a initiation concurrently with COH on cycle day 3 (group II)
Number of subjects: 55
Study 1426320 — intervention group
Group type: COMPARATOR
Intervention: GnRH-a initiation concurrently with COH (group II)
Number of subjects: 55
Study 6320627 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose gum
Number of subjects: 12
Study 6320627 — intervention group
Group type: EXPERIMENTAL
Intervention: Locust bean gum
Number of subjects: 12
Study 6320627 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaya gum
Number of subjects: 12
Study 6320627 — intervention group
Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 12
Study 6320627 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 12
Study 29869538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Coqun (100 mg CQ10, 500 mg Vitamin E TPGS) twice daily for 1 month preoperatively
Number of subjects: 64
Study 29869538 — intervention group
Group type: COMPARATOR
Intervention: No treatment (pseudo-exfoliative glaucoma group)
Number of subjects: 64
Study 29869538 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-exfoliation syndrome (control group)
Number of subjects: 64
Study 29869538 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including malondialdehyde levels)
Number of subjects: 64
Study 29971527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin (n=21)
Number of subjects: 84
Study 29971527 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g OM‐3CA (n=20)
Number of subjects: 84
Study 29971527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dapagliflozin and OM‐3CA (n=22)
Number of subjects: 84
Study 29971527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 84
Study 27787386 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 91
Study 27787386 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Lectures (IL)
Number of subjects: 91
Study 27787386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 25218552 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 78
Study 25218552 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 78
Study 22433020 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (15 mg/kg for 3 weeks)
Number of subjects: 40
Study 22433020 — intervention group
Group type: COMPARATOR
Intervention: Control (regular GINA-guided exacerbation treatment)
Number of subjects: 40
Study 20457725 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural broadband hearing instruments
Number of subjects: 36
Study 20457725 — intervention group
Group type: COMPARATOR
Intervention: Advanced digital hearing instruments
Number of subjects: 36
Study 20457725 — intervention group
Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 36
Study 18506618 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Assertive Community Treatment (IACT)
Number of subjects: 191
Study 18506618 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment Only (ACTO)
Number of subjects: 191
Study 18506618 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 191
Study 18506618 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTO vs IACT
Number of subjects: 191
Study 18506618 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by time interactions
Number of subjects: 191
Study 18506618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation effects
Number of subjects: 191
Study 16186474 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 116
Study 16186474 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 116
Study 12963672 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT) with pharmacotherapy
Number of subjects: 101
Study 12963672 — intervention group
Group type: COMPARATOR
Intervention: Crisis management (CM) with pharmacotherapy
Number of subjects: 101
Study 11054613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 8695248 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (OND) 8 mg x 3 i.v. on day 1 and 8 mg x 2 orally on day 2
Number of subjects: 124
Study 8695248 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 3 mg i.v. on day 1
Number of subjects: 124
Study 8695248 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (OND)
Number of subjects: 124
Study 8695248 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA)
Number of subjects: 124
Study 8695248 — intervention group
Group type: COMPARATOR
Intervention: Preference for Ondansetron (OND)
Number of subjects: 124
Study 8695248 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for Granisetron (GRA)
Number of subjects: 124
Study 8695248 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 124
Study 1809589 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented betamethasone dipropionate (ABD) ointment 0.05% applied in an intermittent pulse dose regimen (three consecutive applications 12 h apart, once a week for a maximum treatment period of 6 months)
Number of subjects: 90
Study 1809589 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study 3891159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego boosting during hypnosis
Number of subjects: 14
Study 3891159 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of a hypnotic state
Number of subjects: 14
Study 3891159 — intervention group
Group type: COMPARATOR
Intervention: Trance state induction (Control)
Number of subjects: 14
Study 30464392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan/Rosuvastatin fixed-dose combination (120 mg fimasartan and 20 mg rosuvastatin)
Number of subjects: 78
Study 30464392 — intervention group
Group type: COMPARATOR
Intervention: Separate co-administration of fimasartan and rosuvastatin
Number of subjects: 78
Study 26708006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Modification intervention (DM‐I)
Number of subjects: 48835
Study 24872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities in the posterior portion of the dorsal medial prefrontal cortex (DmPFC)
Number of subjects: 0
Study 24872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities in the anterior DmPFC
Number of subjects: 0
Study 24872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain signal change in the ventral mPFC
Number of subjects: 0
Study 24872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal anterior cingulate cortex activity
Number of subjects: 0
Study 22264499 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g XOS
Number of subjects: 60
Study 22264499 — intervention group
Group type: EXPERIMENTAL
Intervention: INU‐XOS (3 g inulin + 1 g XOS)
Number of subjects: 60
Study 22264499 — intervention group
Group type: COMPARATOR
Intervention: Wheat maltodextrin (placebo)
Number of subjects: 60
Study 21457067 — intervention group
Group type: EXPERIMENTAL
Intervention: Matsuda insulin sensitivity index (MISI)
Number of subjects: 24
Study 21457067 — intervention group
Group type: EXPERIMENTAL
Intervention: LMTT disposition index (LMTT-DI)
Number of subjects: 24
Study 18095238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) + Metformin (2 g/day)
Number of subjects: 596
Study 18095238 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (Glibenclamide 5 mg/day or Gliclazide 80 mg/day) + Metformin (2 g/day)
Number of subjects: 596
Study 16931991 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus ropivacaine
Number of subjects: 83
Study 16931991 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine
Number of subjects: 83
Study 13678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting with the mandibular impression (easier)
Number of subjects: 48
Study 13678101 — intervention group
Group type: COMPARATOR
Intervention: Starting with the maxillary impression (harder)
Number of subjects: 48
Study 13678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (5 to 6 years)
Number of subjects: 48
Study 10891025 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (information about techniques to help infants at immunization)
Number of subjects: 102
Study 10891025 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 102
Study 10891025 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 102
Study 8832493 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system), 4 inhalations four times per day for 14 days
Number of subjects: 16
Study 8832493 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system), 8 inhalations four times per day for 14 days
Number of subjects: 16
Study 8832493 — intervention group
Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant), 4 inhalations four times per day for 14 days
Number of subjects: 16
Study 8832493 — intervention group
Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant), 8 inhalations four times per day for 14 days
Number of subjects: 16
Study 8832493 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system)
Number of subjects: 16
Study 8832493 — intervention group
Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant)
Number of subjects: 16
Study 1584429 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline monotherapy
Number of subjects: 0
Study 6463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl‐beta‐methylcholine (M)
Number of subjects: 9
Study 6463426 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine phosphate (H)
Number of subjects: 9
Study 6463426 — intervention group
Group type: COMPARATOR
Intervention: Isotonic buffered saline (control)
Number of subjects: 9
Study 31048645 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intravenous antibiotics once on the day of surgery and oral antibiotics for 4 days (Control group)
Number of subjects: 30
Study 31048645 — intervention group
Group type: EXPERIMENTAL
Intervention: No postoperative antibiotics (Experimental group)
Number of subjects: 30
Study 29507938 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antituberculosis therapy
Number of subjects: 331
Study 29507938 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-daily antituberculosis therapy
Number of subjects: 331
Study 29507938 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antituberculosis therapy
Number of subjects: 331
Study 29507938 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 331
Study 27764725 — intervention group
Group type: EXPERIMENTAL
Intervention: H-BE (600-mg total anthocyanins)
Number of subjects: 23
Study 27764725 — intervention group
Group type: COMPARATOR
Intervention: CON (no blackcurrant extract)
Number of subjects: 23
Study 25241758 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 15
Study 23137495 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS)
Number of subjects: 501
Study 23137495 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting metallic stent
Number of subjects: 501
Study 20491843 — intervention group
Group type: EXPERIMENTAL
Intervention: DS with WBV (DS+)
Number of subjects: 10
Study 20491843 — intervention group
Group type: EXPERIMENTAL
Intervention: DS without WBV (DS-)
Number of subjects: 10
Study 20491843 — intervention group
Group type: EXPERIMENTAL
Intervention: SS with WBV (SS+)
Number of subjects: 10
Study 20491843 — intervention group
Group type: EXPERIMENTAL
Intervention: SS without WBV (SS-)
Number of subjects: 10
Study 18025765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 248
Study 18025765 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 248
Study 15644017 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 20
Study 15644017 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 11878655 — intervention group
Group type: COMPARATOR
Intervention: Rectal paracetamol (40-60 mg kg-1 single dose)
Number of subjects: 0
Study 11878655 — intervention group
Group type: COMPARATOR
Intervention: Rectal paracetamol (14-20 mg kg-1 repeat dosing)
Number of subjects: 0
Study 11878655 — intervention group
Group type: COMPARATOR
Intervention: Rectal paracetamol (10-20 mg kg-1 single dose)
Number of subjects: 0
Study 11878655 — intervention group
Group type: COMPARATOR
Intervention: Parenteral paracetamol
Number of subjects: 0
Study 11878655 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + NSAID
Number of subjects: 0
Study 11878655 — intervention group
Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 0
Study 10342698 — intervention group
Group type: EXPERIMENTAL
Intervention: Impregnated bednets
Number of subjects: 0
Study 10342698 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sexually-transmitted disease (STD) treatment services
Number of subjects: 0
Study 7774469 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS (n = 124)
Number of subjects: 329